Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 4 (2007), Issue 4 (April)

1. Proxies and consent discussions for dementia research.
   J Am Geriatr Soc, 55(4): 556-61. [Abstract] [Full-text]
2. Gradient-echo and CRAZED imaging for minute detection of Alzheimer plaques in an APPV717I x ADAM10-dn mouse model.
   Magn Reson Med, 57(4): 696-703. [Abstract] [Full-text]
3. Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome.
   Neurosci Lett, 416(3): 279-84. [Abstract] [Full-text]
4. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.
   Mol Cell Neurosci, 34(4): 621-8. [Abstract] [Full-text]
5. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology.
   Vaccine, 25(16): 3053-6. [Abstract] [Full-text]
6. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
   Vaccine, 25(16): 3041-52. [Abstract] [Full-text]
7. The Nicastrin-like protein Nicalin regulates assembly and stability of the Nicalin-nodal modulator (NOMO) membrane protein complex.
   J Biol Chem, 282(14): 10632-8. [Abstract] [Full-text]
8. Increased frontal phase-locking of event-related theta oscillations in Alzheimer patients treated with cholinesterase inhibitors.
   Int J Psychophysiol, 64(1): 46-52. [Abstract] [Full-text]
9. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
   Neurology, 68(14): 1116-21. [Abstract] [Full-text]
10. Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.
    Trends Mol Med, 13(4): 135-42. [Abstract] [Full-text]
11. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Toxicology, 233(1): 60-9. [Abstract] [Full-text]
12. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia.
    J Psychiatr Res, 41(8): 686-93. [Abstract] [Full-text]
13. Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin.
    J Psychiatr Res, 41(8): 694-701. [Abstract] [Full-text]
14. Understanding the molecular basis for the inhibition of the Alzheimer's Abeta-peptide oligomerization by human serum albumin using saturation transfer difference and off-resonance relaxation NMR spectroscopy.
    J Am Chem Soc, 129(14): 4282-90. [Abstract] [Full-text]
15. Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease.
    Clin Chem, 53(4): 657-65. [Abstract] [Full-text]
16. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
    J Neurosci, 27(14): 3639-49. [Abstract] [Full-text]
17. Magnetic resonance analysis of amygdalar volume in Alzheimer's disease.
    Curr Opin Psychiatry, 20(3): 273-7. [Abstract] [Full-text]
18. Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation.
    Neuroreport, 18(6): 559-63. [Abstract] [Full-text]
19. Ida's gift.
    Nursing, 37(4): 45. [Abstract] [Full-text]
20. Plasma Abeta levels do not reflect brain Abeta levels.
    J Neuropathol Exp Neurol, 66(4): 264-71. [Abstract] [Full-text]
21. Copper and Alzheimer's disease.
    Curr Opin Chem Biol, 11(2): 128-33. [Abstract] [Full-text]
22. Structure and dynamics of parallel beta-sheets, hydrophobic core, and loops in Alzheimer's A beta fibrils.
    Biophys J, 92(9): 3032-9. [Abstract] [Full-text]
23. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
    J Biol Chem, 282(15): 11436-45. [Abstract] [Full-text]
24. Physical activity and white matter lesion progression: assessment using MRI.
    Neurology, 68(15): 1223-6. [Abstract] [Full-text]
25. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
    Neurology, 68(15): 1205-12. [Abstract] [Full-text]
26. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.
    Arch Neurol, 64(4): 583-7. [Abstract] [Full-text]
27. Clinical and psychometric distinction of frontotemporal and Alzheimer dementias.
    Arch Neurol, 64(4): 535-40. [Abstract] [Full-text]
28. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort.
    Arch Neurol, 64(4): 501-6. [Abstract] [Full-text]
29. Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers.
    Expert Rev Proteomics, 4(2): 227-38. [Abstract] [Full-text]
30. Multiple imputation for the comparison of two screening tests in two-phase Alzheimer studies.
    Stat Med, 26(11): 2370-88. [Abstract] [Full-text]
31. Performance on the Mini-Mental State Examination and Mattis Dementia Rating Scale among older American Indians.
    J Neuropsychiatry Clin Neurosci, 19(2): 173-8. [Abstract] [Full-text]
32. Brain structural alterations before mild cognitive impairment.
    Neurology, 68(16): 1268-73. [Abstract] [Full-text]
33. Fronto-temporal-lobe atrophy in early-stage Alzheimer's disease identified using an improved detection methodology.
    Psychiatry Res, 155(1): 11-9. [Abstract] [Full-text]
34. Long-term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease.
    Life Sci, 80(20): 1897-905. [Abstract] [Full-text]
35. In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease.
    Neuroimage, 35(4): 1401-8. [Abstract] [Full-text]
36. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia.
    Brain, 130: 1159-66. [Abstract] [Full-text]
37. Beta-amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress.
    Neurobiol Dis, 26(2): 342-52. [Abstract] [Full-text]
38. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels.
    J Neurosci, 27(16): 4385-95. [Abstract] [Full-text]
39. Focal atrophy and cerebrovascular disease increase dementia risk among cognitively normal older adults.
    J Neuroimaging, 17(2): 148-55. [Abstract] [Full-text]
40. Linguistic changes in verbal expression: a preclinical marker of Alzheimer's disease.
    J Int Neuropsychol Soc, 13(3): 433-9. [Abstract] [Full-text]
41. A predominance of category deficits for living things in Alzheimer's disease and Lewy body dementia.
    J Int Neuropsychol Soc, 13(3): 401-9. [Abstract] [Full-text]
42. Diffusion tensor imaging of the brain in patients with Alzheimer's disease and cerebrovascular lesions.
    J Zhejiang Univ Sci B, 8(4): 242-7. [Abstract] [Full-text]
43. Mutant presenilin 2 increased oxidative stress and p53 expression in neuronal cells.
    Biochem Biophys Res Commun, 357(1): 174-80. [Abstract] [Full-text]
44. Familial Alzheimer's disease presenilin 1 mutation M146V increases gamma secretase cutting of p75NTR in vitro.
    Brain Res, 1147: 248-55. [Abstract] [Full-text]
45. Polymorphisms of cholesterol metabolism genes CYP46 and ABCA1 and the risk of sporadic Alzheimer's disease in Chinese.
    Brain Res, 1147: 34-8. [Abstract] [Full-text]
46. No association of vacuolar protein sorting 26 polymorphisms with Alzheimer's disease.
    Neurobiol Aging, 28(6): 883-4. [Abstract] [Full-text]
47. Increased susceptibility to amyloid toxicity in familial Alzheimer's fibroblasts.
    Neurobiol Aging, 28(6): 863-76. [Abstract] [Full-text]
48. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.
    Neurobiol Aging, 28(6): 824-30. [Abstract] [Full-text]
49. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms.
    Neurobiol Aging, 28(6): 831-44. [Abstract] [Full-text]
50. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease.
    Neurobiol Aging, 28(6): 856-62. [Abstract] [Full-text]
51. Alzheimer's disease patients' cognitive status and course years prior to symptom recognition.
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn, 14(3): 227-35. [Abstract] [Full-text]
52. Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias.
    Neurosci Lett, 418(1): 72-6. [Abstract] [Full-text]
53. p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells.
    Neurosci Lett, 418(1): 34-7. [Abstract] [Full-text]
54. Fifty Hertz electromagnetic field exposure stimulates secretion of beta-amyloid peptide in cultured human neuroglioma.
    Neurosci Lett, 418(1): 9-12. [Abstract] [Full-text]
55. Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer's disease therapy.
    Phytother Res, 21(5): 423-6. [Abstract] [Full-text]
56. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease.
    Mol Psychiatry, 12(5): 510-7. [Abstract] [Full-text]
57. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.
    J Cereb Blood Flow Metab, 27(5): 909-18. [Abstract] [Full-text]
58. White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques.
    Radiology, 243(2): 483-92. [Abstract] [Full-text]
59. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
    Am J Pathol, 170(5): 1669-75. [Abstract] [Full-text]
60. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.
    Parkinsonism Relat Disord, 13(4): 224-9. [Abstract] [Full-text]
61. Retinal abnormalities in early Alzheimer's disease.
    Invest Ophthalmol Vis Sci, 48(5): 2285-9. [Abstract] [Full-text]
62. Novel styrylpyridines as probes for SPECT imaging of amyloid plaques.
    J Med Chem, 50(9): 2157-65. [Abstract] [Full-text]
63. Progressive topographical disorientation: a case of focal Alzheimer's disease.
    Neurol Sci, 28(2): 107-10. [Abstract] [Full-text]
64. Hallucinations and sleep-wake cycle in Alzheimer's disease: a questionnaire-based study in 218 patients.
    Neurol Sci, 28(2): 96-9. [Abstract] [Full-text]
65. The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease.
    Neurol Sci, 28(2): 80-6. [Abstract] [Full-text]
66. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
    Neurol Sci, 28(2): 63-71. [Abstract] [Full-text]
67. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease.
    Am J Geriatr Psychiatry, 15(5): 435-7. [Abstract] [Full-text]
68. Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents.
    Am J Geriatr Psychiatry, 15(5): 376-85. [Abstract] [Full-text]
69. Effective pharmacologic management of Alzheimer's disease.
    Am J Med, 120(5): 388-97. [Abstract] [Full-text]
70. Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease.
    NMR Biomed, 20(3): 343-51. [Abstract] [Full-text]
71. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.
    Clin Chem, 53(5): 859-65. [Abstract] [Full-text]
72. Swedish amyloid precursor protein mutation increases phosphorylation of eIF2alpha in vitro and in vivo.
    J Neurosci Res, 85(7): 1528-37. [Abstract] [Full-text]
73. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach.
    J Neurosci Res, 85(7): 1506-14. [Abstract] [Full-text]
74. A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging.
    J Neurosci Res, 85(7): 1538-46. [Abstract] [Full-text]
75. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.
    Exp Neurol, 205(1): 166-76. [Abstract] [Full-text]
76. Association studies between the plasmin genes and late-onset Alzheimer's disease.
    Neurobiol Aging, 28(7): 1041-3. [Abstract] [Full-text]
77. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites.
    Neurobiol Aging, 28(7): 987-94. [Abstract] [Full-text]
78. 82-kDa choline acetyltransferase is in nuclei of cholinergic neurons in human CNS and altered in aging and Alzheimer disease.
    Neurobiol Aging, 28(7): 1028-40. [Abstract] [Full-text]
79. Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease.
    Neurobiol Aging, 28(7): 1015-27. [Abstract] [Full-text]
80. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease.
    Neurobiol Aging, 28(7): 977-86. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.